1. Frontier Pharma: Melanoma Therapeutics-Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Phone No.: +1 (214) 884-6817 Email id: sales@orbisresearch.com

2. Frontier Pharma: Melanoma Therapeutics-Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly affects the skin, as cutaneous melanoma; however it can also affect other pigmented tissues, such as the eye or intestines, as extracutaneous melanoma. It is the deadliest form of skin cancer and remains one of the most aggressive and treatment-resistant human cancers. Request a sample of this report @ http://www.orbisresearch.com/contacts/request- sample/193024.http://www.orbisresearch.com/contacts/request- sample/193024 In spite of these developments, there are still significant unmet needs for both cutaneous and extracutaneous melanoma, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the melanoma pipeline, which is substantially larger than the current market. Phone No.: +1 (214) 884-6817 Email id: sales@orbisresearch.com

3. About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors accross the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Information: 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817 enquiry@orbisresearch.com sales@orbisresearch.com Phone No.: +1 (214) 884-6817 Email id: sales@orbisresearch.com Frontier Pharma: Melanoma Therapeutics-Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation